Skip to Main Content

++

INTRODUCTION

++

finasteride (fi-nas-teer-ide)

Propecia, Proscar

Classification

Therapeutic: hair regrowth stimulants

Pharmacologic: androgen inhibitors

++
Indications
++

Benign prostatic hyperplasia (BPH); can be used with doxazosin. Androgenetic alopecia (male pattern baldness) in men only.

++
Action
++

Inhibits the enzyme 5-alpha-reductase, which is responsible for converting testosterone to its potent metabolite 5-alpha-dihydrotestosterone in prostate, liver, and skin; 5-alpha-dihydrotestosterone is partially responsible for prostatic hyperplasia and hair loss. Therapeutic Effects: Reduced prostate size with associated decrease in urinary symptoms. Decreases hair loss; promotes hair regrowth.

++
Adverse Reactions/Side Effects
++

GU: decreased libido, decreased volume of ejaculate, erectile dysfunction.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • When treating BPH, monitor signs such as difficulty starting a urine stream, painful urination, weak urine flow, feeling that the bladder is not completely empty, frequent nighttime urination, and an urge to urinate again soon after urinating. Document any change in BPH symptoms to help assess the effects of drug therapy.

++
Interventions
++

  • When appropriate, design and implement resistive exercise programs to help maintain muscle strength and bone integrity to offset the musculoskeletal effects of diminished 5-alpha-dihydrotestosterone biosynthesis.

++
Patient/Client-Related Instruction
++

  • When treating BPH, advise patient that urinary symptoms (retention, dribbling, hesitancy, urgency) should improve, and to contact the physician if these symptoms continue to worsen.

  • Instruct patient to report other bothersome side effects such as decreased libido or erectile dysfunction.

++
Pharmacokinetics
++

Absorption: Well absorbed after oral administration (63%).

++

Distribution: Enters prostatic tissue and crosses the blood-brain barrier. Remainder of distribution not known.

++

Protein Binding: 90%.

++

Metabolism and Excretion: Mostly metabolized; 39% excreted in urine as metabolites; 57% excreted in feces.

++

Half-life: 6 hr (range 6–15 hr; slightly increased in patients >70 yr).

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE (reduction in dihydrotestosterone levels*)

ROUTE ONSET PEAK DURATION
PO rapid 8 hr 2 wk

*Clinical effects as noted by urinary tract symptoms and hair regrowth may not be evident for several months and remain for 4 mo after discontinuation.

++
Contraindications/Precautions
++

Contraindicated in: Hypersensitivity; Women.

++

Use Cautiously in: Patients with hepatic impairment or obstructive uropathy.

++
Interactions
++

Drug-Drug: None noted.

++
Route/Dosage
++

PO (Adults): BPH—5 mg once daily (Proscar); androgenetic alopecia—1 mg/day (Propecia).

++
Availability (generic available)
++

Tablets: 1 mg (Propecia), 5 mg (Proscar).

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.